Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Angiomax vs Heparin/Protamine in OPCAB Surgery
NCT00073593Phase 3Completed
- Sponsor
- The Medicines Company
- Start
- Aug 2003
- Primary completion
- May 2004
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bivalirudin in coronary artery disease (CAD) (2 arms), sponsored by The Medicines Company. Primary endpoints: Death at Day 7, Q-wave Myocardial Infarction at Day 7 and 2 more. Started Aug 2003; status: completed.
02
Drugs
bivalirudin
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT00073593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00073593.